REDWOOD CITY, Calif., March 29 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. , today announced multiple presentations regarding its oncology pipeline, which includes glufosfamide for the treatment of pancreatic cancer, 2-deoxyglucose (2DG) for solid tumors and preclinical therapeutic candidates. The presentations will take place at the 2006 American Association for Cancer Research (AACR) annual meeting being held April 1-5, 2006, at the Washington Convention Center in Washington, D.C.
The planned presentations are as follows: Sunday, April 2, 2006 Abstract 515: Phase 1 trial of Glycolytic Inhibition with 2-Deoxyglucose and Docetaxel for Patients with Solid Tumors (8:00a.m.) Abstract 1359: A Cell-Based Screening Platform for Hypoxia-Activated Prodrugs (1:00p.m.) Tuesday, April 4, 2006 Abstract 4738: A Novel Alkylating Agent, Glufosfamide, Enhances Activity of Gemcitabine in Models of Pancreatic Cancer (1:00p.m.) Wednesday, April 5, 2006 Abstract 5540: Characterization of ARC-111 as a TOP 1/HIF 1-alpha Inhibitor (8:00a.m.) About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery, development and commercialization of small molecule therapeutics in middle- and late-stage clinical trials for the potential treatment of benign prostatic hyperplasia (BPH), a disease afflicting tens of millions of men worldwide, and cancer. By selectively targeting tumor or other abnormally-proliferating cells, the Company’s drug candidates are designed to be potentially more effective and less toxic to healthy tissues than conventional treatments. For additional information, please visit our website (www.thresholdpharm.com).
Contact: Denise T. Powell Carolyn Bumgardner Wang Sr. Director, Corporate Communications WeissComm Partners, Inc. Threshold Pharmaceuticals, Inc. 415-946-1065 650-474-8206 carolyn@weisscommpartners.comdpowell@thresholdpharm.com
Threshold Pharmaceuticals, Inc.
CONTACT: Denise T. Powell, Sr. Director, Corporate Communications ofThreshold Pharmaceuticals, Inc., +1-650-474-8206, ordpowell@thresholdpharm.com, or Carolyn Bumgardner Wang of WeissCommPartners, Inc., +1-415-946-1065, or carolyn@weisscommpartners.com, forThreshold Pharmaceuticals, Inc.
Web site: http://www.thresholdpharm.com/
